A detailed history of Bridgeway Capital Management, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 311,000 shares of ADGI stock, worth $1.03 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
311,000
Previous 325,300 4.4%
Holding current value
$1.03 Million
Previous $1.08 Million 4.37%
% of portfolio
0.02%
Previous 0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
N/A
-14,300 Reduced 4.4%
311,000 $1.03 Million
Q1 2024

May 15, 2024

SELL
N/A
-185,600 Reduced 36.33%
325,300 $1.08 Million
Q4 2023

Feb 14, 2024

BUY
N/A
66,000 Added 14.83%
510,900 $1.69 Million
Q3 2023

Nov 14, 2023

BUY
N/A
146,800 Added 49.25%
444,900 $1.47 Million
Q2 2023

Aug 14, 2023

SELL
N/A
-10,000 Reduced 3.25%
298,100 $986,000
Q1 2023

May 15, 2023

BUY
N/A
308,100 New
308,100 $1.02 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.